BeiGene Ltd
(FRA:49BA)
€
152
5 (3.4%)
Market Cap: 15.89 Bil
Enterprise Value: 14.28 Bil
PE Ratio: 0
PB Ratio: 5.18
GF Score: 69/100 - Beigene Ltd at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Beigene Ltd Investors and Analysts Panel Event Presentation TranscriptDec 11, 2023
- Beigene Ltd at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Beigene Ltd Investor Research and Development Day TranscriptJul 18, 2023
- Beigene Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2023
- Beigene Ltd at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Beigene Ltd to Discuss Final Results of the ALPINE Trial Late-Breaker Presentation TranscriptDec 13, 2022
- Beigene Ltd to Discuss Final Results of the ALPINE Trial Q&A Call TranscriptDec 12, 2022
- Beigene Ltd at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Beigene Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Beigene Ltd at Cowen Health Care Conference (Virtual) TranscriptMar 07, 2022
- Beigene Ltd at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 10, 2022
- Beigene Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- Beigene Ltd R&D Day TranscriptAug 25, 2021
- Beigene Ltd to Discuss Interim Analysis of the ALPINE Trial and Data Presented at EHA2021 Call TranscriptJun 11, 2021
- Beigene Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Beigene Ltd China National Reimbursement Drug List (NRDL) Results Conference Call TranscriptDec 29, 2020
- Beigene Ltd at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Beigene Ltd to Discuss the Company's Early Development Pipeline and Research Call TranscriptJul 09, 2020
- Beigene Ltd at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- Beigene Ltd at American Society of Clinical Oncology (ASCO) Virtual Scientific Program Call TranscriptMay 30, 2020
- Beigene Ltd at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Beigene Ltd Update Call: ASPEN Trial Readout TranscriptDec 16, 2019
- Beigene Ltd Corporate Update: Global Strategic Oncology Collaboration with Amgen TranscriptNov 01, 2019
- Beigene Ltd at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Beigene Ltd Update Call TranscriptSep 08, 2019
- Beigene Ltd Conference Call to Discuss Clinical Data on Zanubrutinib at 15th International Conference on Malignant Lymphoma (ICML) TranscriptJun 20, 2019
- Beigene Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2019
- Beigene Ltd at Barclays Global Healthcare Conference TranscriptMar 13, 2019
- Q4 2018 Beigene Ltd Earnings Call TranscriptFeb 27, 2019€122.52 (+0.96%)Earnings
Beigene Ltd at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 10, 2022 / 02:00PM GMT
Release Date Price:
€190
(+4.40%)
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
Welcome. My name is Michael Schmidt. I'm one of the biotech analysts at Guggenheim and it is my great pleasure to welcome the next company, BeiGene. With us today, we have John Oyler, Co-Founder and CEO. John, thanks so much for joining us and welcome.
John V. Oyler
BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO
Thanks, happy to be here.
Questions & Answers
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
So I think I'll just start with a big picture question. BeiGene is obviously now one of the largest global biotech companies. Perhaps, John, if you -- could you briefly just highlight how the strategy of the company has been in recent years?
John V. Oyler
BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO
Sure. Happy to do that. I think BeiGene started about 12 years ago. And from the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)